)
Alector (ALEC) investor relations material
Alector Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 net income was $124.6 million, primarily reflecting recognition of $162.9 million in remaining GSK deferred revenue after performance obligations ended.
AL050 was licensed exclusively worldwide to Genentech for $100.0 million upfront, up to $1.17 billion in milestones and tiered royalties; the ABC platform was retained.
Pipeline focus shifted to ABC-enabled programs after GSK programs were discontinued; no active clinical trials were reported.
Financial highlights
Q3 collaboration revenue was $162.9 million vs. $3.3 million YoY, primarily from recognition of remaining GSK deferred revenue.
Q3 operating income was $123.8 million vs. an operating loss of $37.6 million YoY; net income was $124.6 million vs. a net loss of $34.7 million.
Q3 R&D was $30.0 million vs. $29.4 million; G&A was $9.0 million vs. $11.5 million YoY.
9M revenue was $167.2 million vs. $14.8 million; net income was $78.7 million vs. a net loss of $105.7 million.
9M R&D was $67.4 million vs. $90.6 million and G&A was $25.4 million vs. $40.6 million, mainly reflecting lower personnel costs after workforce reductions.
Outlook and guidance
Cash, cash equivalents and investments, plus the Genentech upfront payment and October offering proceeds net of the Spur payment, are expected to fund operations into 2H 2029; estimates depend on assumptions that may change.
AL137 first-in-human SC dosing in Australia is targeted by April 2027, with a U.S. IND submission targeted for Q2 2027; AL164 and AL062 first-in-human studies are targeted for Q2 2028.
R&D spending on latozinemab and nivisnebart is expected to decline as trials wind down, while investment continues in research and preclinical programs.
- Genentech’s AL050 license funds a brain-enabled pipeline, with AL137 leading toward clinic.ALEC
Investor update - ABC platform enables next-gen brain therapeutics, with clinical data and partnering on the horizon.ALEC
Morgan Stanley 24th Annual Global Healthcare Conference - ABC platform delivers brain-penetrant therapies with strong preclinical efficacy and strategic value.ALEC
Corporate presentation - Lead anti-Aβ antibody AL137 enters clinic soon, with robust pipeline and partnering for Parkinson's assets.ALEC
12th Annual Cantor Fitzgerald Global Healthcare Conference - Advanced ABC platform pipeline, reduced net loss, and cash runway extends through 2027.ALEC
Q2 2026 - Brain carrier platform enables next-gen CNS therapies with superior brain delivery and safety.ALEC
Corporate presentation - CB-010 and CB-011 prioritized for scalable, durable cell therapies, with cash runway into 2027.ALEC
BofA Securities 2025 Healthcare Conference - ABC platform achieves high-efficiency brain delivery for diverse therapies, advancing CNS drug innovation.ALEC
Status Update - Pivotal FTD-GRN phase III data and AL101 phase II enrollment expected in 2025, backed by strong liquidity.ALEC
Q4 2024
)
)
)
)
)
)
)
)